Sepsis Diagnostics Market Trends

Growth Drivers

Growing Prevalence of Hospital-Acquired Infections – Hospital-acquired infections (HAIs), also known as nosocomial infections, are a major cause of morbidity and mortality worldwide. Urinary tract infections, pneumonia, and sepsis are the most frequent Hospital Acquired Infections. HAIs can lead to sepsis in immunocompromised patients, geriatric patients, and patients suffering from chronic illnesses. For instance, in the United States, there is an increase in sepsis by 8.7% annually among patients admitted to a hospital. It is estimated that more than 1,000,000 cases of sepsis among hospitalized patients occur each year in the United States.
Development of Rapid Diagnostic Techniques for Sepsis Diagnosis – Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6%. Therefore, there is an increasing need to develop diagnostic tools for sepsis. Hence, the BACTEC Plus and BACTEC FX blood culturing instruments manufactured by BD Company (US) an automated microbial detection system offering a rapid diagnosis of sepsis in a turnaround time of three hours. Increase in Funding for Sepsis-Related Research Activities – According to the most recent reports, sepsis funding and directives have been included in the USD 1.7 trillion Omnibus spending bill passed and signed by President Joe Biden in January 2023. It is predicted that this boom would continue over the forecast period.
Increasing Burden of Sepsis – the global sepsis mortality rate is reported as 11 million in the year 2019. Reports from WHO cite that 85% of sepsis cases occur in low and middle-income countries. This increasing burden of sepsis is hence expected to contribute to the growth of the market in the forecast period.

Challenges

High cost of diagnostic devices - The increasing concern amongst people about the high cost of diagnostic devices is one of the major factors predicted to slow down the market growth. The cost of molecular diagnostic tests is between USD 300 and USD 3,000, which is very high compared to the cost of blood culture tests priced as low as ~USD 28–35.
Shortage of skilled healthcare professionals
Lack of appropriate testing for sepsis

Sepsis Diagnostics Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	11.8%
Base Year Market Size (2024)	USD 2.5 billion
Forecast Year Market Size (2037)	USD 10.79 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of sepsis diagnostics is evaluated at USD 2.74 billion.

The sepsis diagnostics market size was valued at USD 2.5 billion in 2024 and is likely to exceed USD 10.79 billion by the end of 2037, expanding at over 11.8% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of hospital-acquired infections, the rising burden of sepsis in the world, and rising diagnostic developments will boost the market growth.

North America industry is set to hold 39% of the revenue share by 2037, due to increasing and developed healthcare infrastructure in the region.

The major players in the market include BioMÃ©rieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Cepheid, Beckman Coulter, Inc., Amara Health Analytics, Wolters Kluwer N.V., Cerner Corp.

Sepsis Diagnostics Market Trends